Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7015928 | 1.00 | ITGB1 (0.46) | ITGB1ITGA4ADRB3KMT2APOLB | |
| SCHEMBL19544075 | 0.88 | ITGAV (0.39) | ITGB1ITGA4ADRB3POLBALDH1A1 | |
| SCHEMBL17262997 | 0.84 | ADRB3 (0.38) | ITGB1ITGA4ADRB3KMT2APOLB | |
| SCHEMBL13719466 | 0.84 | ADRB3 (0.38) | ITGB1ITGA4ADRB3KMT2APOLB | |
| SCHEMBL5091427 | 0.84 | ITGB1 (0.48) | ITGB1ITGA4KMT2APOLBALDH1A1 | |
| SCHEMBL6221566 | 0.78 | ITGB3 (0.50) | KMT2APOLBALDH1A1ITGB3ITGA2B | |
| SCHEMBL13719471 | 0.77 | KMT2A (0.38) | ADRB3KMT2APOLBALDH1A1KCNK3 | |
| SCHEMBL20139059 | 0.76 | KCNK3 (0.43) | ITGB1ITGA4ADRB3KMT2APOLB | |
| SCHEMBL20140573 | 0.76 | ITGB1 (0.47) | ITGB1ITGA4KMT2APOLBALDH1A1 | |
| SCHEMBL3727872 | 0.75 | NNMT (0.47) | ITGB1ITGA4KMT2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349968-A1 | Compositions and Methods for Treating Cancer | ARIAD PHARMACEUTICALS, INC. (US) | 2014-11-27 | — | — | US | disclosed |
| EP-1252162-B1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1252162-A4 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-1252162-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-6472403-B2 | IMIDAZOLIDIN-2-ONE DERIVATIVES; INHIBITING BONE RESORPTION, VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, ARTHRITIS, VIRAL DISEASE, CANCER AND METASTATIC TUMOR GROWTH | MERCK & CO., INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020037889-A1 | Alpha V integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-03-28 | — | — | US | disclosed |
| WO-2001053297-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349968-A1 | Compositions and Methods for Treating Cancer | ITGB3, MTOR, ITGA2 | ITGB1 9/4885ITGA4 7/4885ADRB3 989/4885 |
| US-20020037889-A1 | Alpha V integrin receptor antagonists | ITGAV, ITGB3, ITGA5 | ITGB1 5/4885ITGA4 14/4885ADRB3 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.